FDA's AI Drug Watch: Comment on Safety Tech Revolution
Published Date: 2/18/2026
Notice
Summary
The FDA is asking for public feedback on a new plan to use smart technology like AI to better track drug safety after medicines hit the market. This affects drug companies who must report safety info and could speed up how quickly problems are spotted. Comments are open until March 20, 2026, so now’s the time to weigh in on this tech upgrade that aims to keep medicines safer and reporting smoother.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 1 costs, 1 mixed.
Industry Meeting Burden: 10–30 Hours
If your organization wants to present to FDA under the Emerging Drug Safety Technology Program, you must prepare an initial meeting proposal (about 10 hours). If selected, you must prepare and deliver a 20–50 minute presentation, which FDA estimates will take about 30 hours. FDA estimates 25 organizations will request presentations per year, about 12 meetings will be held per year, and the total annual burden across respondents is 610 hours.
Faster Drug Safety Detection
The FDA says using AI and other emerging technologies in postmarket pharmacovigilance could create more efficiencies and help spot safety problems sooner. The Emerging Drug Safety Technology Program is meant to accelerate FDA's understanding of these tools so problems with medicines may be identified more quickly.
May Shape Future AI Drug Rules
FDA will use information from Emerging Drug Safety Technology meetings to inform potential regulatory and policy approaches for AI and other emerging technologies in postmarket safety surveillance. If your organization develops or uses AI for pharmacovigilance, what you share could influence future FDA policies.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12239 — Agency Information Collection Activities; Proposed Collection; Comment Request; Extralabel Drug Use in Animals
The FDA wants your thoughts on how they collect info about using drugs in animals in ways not originally approved (called extralabel use). This affects vets, farmers, and animal drug makers who report this info. You’ve got until August 17, 2026, to share your comments—no cost changes, just making sure the paperwork is clear and easy.
2026-12236 — SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams
SpecGx LLC has asked the FDA to withdraw its approval for three strengths (27 mg, 36 mg, and 54 mg) of its methylphenidate extended-release tablets, effective June 18, 2026. This means these specific versions of the medicine will no longer be allowed on the market. Patients and pharmacies using these doses should look for alternatives, but no extra costs or penalties are mentioned.
2026-12235 — Advisory Committee; Science Board to the Food and Drug Administration; Renewal
The FDA is renewing its Science Board for two more years, keeping expert advice flowing to help ensure safe and effective drugs and products. This renewal affects scientists and public health folks who guide the FDA’s big decisions, with the new term lasting until June 26, 2028. No extra costs or delays are expected—just more smart brains working for your health!
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
2026-12238 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements
The FDA is asking for public feedback by July 20, 2026, on their rules that keep dietary supplements safe and made right. These rules affect companies that make, package, label, or store supplements, helping ensure products are high quality without adding extra costs. This review keeps the safety standards up-to-date and clear for everyone involved.
2026-12237 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles and Medicated Feeds
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.
Previous / Next Documents
Previous: 2026-03091 — Agency Information Collection Activities; Proposed eCollection eComments Requested; Title-National Incident-Based Reporting System (NIBRS)
The FBI wants to keep collecting crime data through the National Incident-Based Reporting System (NIBRS) and is asking for your feedback on how to make it easier and better. This affects law enforcement agencies who report crime info and could save them time with improved electronic forms. You’ve got until March 20, 2026, to share your thoughts before the government decides on the final plan.
Next: 2026-03094 — Agency Information Collection Activities; Proposed Collection; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA wants your thoughts on how they collect info about patent term restoration and due diligence petitions. This affects companies dealing with drug patents who file petitions to extend patent life. Comments are open until April 20, 2026, so get ready to share your views—no fees, just your input!